This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Cardiomyopathy	Apolipoprotein O (APOO)	*In vitro* and mouse studies suggest inhibiting cardiac APOO could help treat diabetes-associated cardiomyopathy. *APOO* is elevated in hearts of patients with diabetes. In mice overexpressing human *APOO* and fed a high-fat diet, ventricular function was decreased compared with that in wild-type mice. In cultured rat cardiac myoblasts, overexpression of *Apoo* increased respiration and mitochondrial uncoupling compared with wild-type *Apoo* expression and led to reactive oxygen species generation, lipotoxicity and cell death. Next steps could include developing an APOO inhibitor. *SciBX* 7(21); doi:10.1038/scibx.2014.615 **Published online May 29, 2014**	Findings patented; available for licensing	Turkieh, A. *et al. J. Clin. Invest.*; published online April 17, 2014; doi:10.1172/JCI74668 **Contact:** Fatima Smith, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France e-mail: fatima.smith-rouet@inserm.fr